Skip to main content
Oncopeptides logo

Oncopeptides — Investor Relations & Filings

Ticker · ONCO ISIN · SE0009414576 LEI · 549300J9WWQ5CBYQ1M77 ST Manufacturing
Open in API
Filings indexed 483 across all filing types
Latest filing 2024-04-29 AGM Information
Country SE Sweden
Listing ST ONCO

About Oncopeptides

https://www.oncopeptides.com/en

Oncopeptides is a biotechnology company focused on the research, development, and commercialization of targeted therapies for difficult-to-treat cancers. The company concentrates on hematological diseases, with a primary focus on multiple myeloma. Its commercialized product is Pepaxti (melflufen), a peptide-drug conjugate for adult patients with relapsed or refractory multiple myeloma. Founded in 2000 based on research from leading cancer institutions, Oncopeptides leverages its proprietary technology platforms to advance a pipeline of innovative drug candidates. The company's research also includes the development of Natural Killer (NK) cell engagers to address unmet medical needs in oncology.

Recent filings

Filing Released Lang Actions
Annual General Meeting in Oncopeptides AB (publ)
AGM Information Classification · 1% confidence The document explicitly states in the title and throughout the text that it is a notice for the "Annual General Meeting in Oncopeptides AB (publ)". It details the date, location, registration procedures, proposed agenda items (including elections, approval of financial statements, and remuneration reports), and specific proposals related to shareholder programs. This content perfectly matches the definition of materials related to an Annual General Meeting (AGM). The code for AGM materials is AGM-R.
2024-04-29 English
Annual Report (ESEF) 2023
Annual Report (ESEF) Classification · 1% confidence FY 2023
2024-04-22 Swedish
Oncopeptides offentliggör prospekt avseende företrädesemissionen
Capital/Financing Update Classification · 1% confidence The document is a press release from Oncopeptides AB announcing that the prospectus for a rights issue (företrädesemission) has been approved and registered by the Swedish Financial Supervisory Authority (Finansinspektionen) and is now available. The text explicitly mentions the approval and availability of the 'prospekt' (prospectus) and provides details about the offering period and advisors. This document is not the full prospectus itself, but rather the announcement of its publication and availability. According to Rule 2, if a document is short and announces the publication of a report (like a prospectus), it should be classified as a Report Publication Announcement (RPA). The document is relatively short (under 10,000 characters) and its primary function is to announce the publication of the prospectus, which is a key financing document.
2024-04-17 Swedish
Oncopeptides publishes prospectus relating to the rights issue
Capital/Financing Update Classification · 1% confidence The document is a press release titled "Oncopeptides publishes prospectus relating to the rights issue." It explicitly states that the prospectus for the Rights Issue has been approved and registered by the Swedish Financial Supervisory Authority and is now available. The core subject is the announcement of the availability of a prospectus related to a capital raising activity (Rights Issue). Since the document is an announcement about the publication of a formal document (the prospectus) rather than the prospectus itself, and it details financing/capital activities, it aligns best with the Capital/Financing Update (CAP) category, which covers fundraising and capital structure changes. While it mentions the prospectus, the primary action reported is the financing event and the subsequent availability of the related document. Given the context of a rights issue announcement, CAP is the most specific fit over a general RPA or RNS.
2024-04-17 English
Bulletin from an Extraordinary General Meeting in Oncopeptides AB (publ)
AGM Information Classification · 1% confidence The document is explicitly titled 'Bulletin from an Extraordinary General Meeting in Oncopeptides AB (publ)' and details resolutions passed at this meeting. The resolutions concern amending articles of association and approving a rights issue (a capital/financing activity). Since the document reports the outcomes of a shareholder meeting, it relates to AGM information or voting results. However, the core content is the resolution of the EGM, which directly impacts the share structure (share capital increase, rights issue). The closest fit among the provided codes is 'AGM-R' (AGM Information) as it is a bulletin from a General Meeting. While it details a capital change, the context is the meeting outcome, not just the financing announcement itself. Given the explicit mention of an 'Extraordinary General Meeting', AGM-R is the most appropriate classification.
2024-04-15 English
Kommuniké från Extra Bolagsstämma i Oncopeptides AB (publ)
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document is titled "Kommuniké från Extra Bolagsstämma i Oncopeptides AB (publ)" which translates to 'Communiqué from the Extraordinary General Meeting in Oncopeptides AB (publ)'. It details the resolutions passed at the EGM held on April 15, 2024, specifically concerning changes to the articles of association and approval of a rights issue. Since it reports the decisions made at a general meeting, it directly relates to shareholder voting outcomes. The most appropriate classification is 'Declaration of Voting Results & Voting Rights Announcements' (DVA). Although it relates to a capital change (CAP), the primary context is the formal outcome of the shareholder meeting.
2024-04-15 Swedish

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.